Regulatory Affairs Careers in 2026: Education, Certifications, and Salary Benchmarks
Note: 1 USD ≈ 100 RUB. Ruble figures are gross monthly unless stated otherwise.
A Head of Pharmacovigilance (PV) at a multinational earns ₽380,000/month (~$3,800). A counterpart at a Russian domestic company in the same role earns roughly half that. A Regulatory Affairs Director at a major pharmaceutical holding crosses the ₽1,000,000 mark (~$10,000), while an entry-level specialist starts at ₽80,000 (~$800) and can multiply that several times over five to seven years.
For a long time, Regulatory Affairs (RA) was considered a quiet backwater for those who preferred paperwork to the limelight — «boring administrative work» for people who had drifted away from the lab or the pharmacy counter. Then December 31, 2025 arrived. The deadline for transitioning to EAEU (Eurasian Economic Union) registration passed, the transition period was extended to 2027, and the hiring landscape shifted sharply.
Companies now need specialists who understand Eurasian procedures. Those who only know national systems are losing ground. Experts estimate a talent shortage of up to 30% by the end of 2026, so employers are competing for professionals — offering remote work, flexible hours, and compensation packages that looked implausible just three years ago.
The RA Director has become a strategic business partner. No product reaches the shelf without their sign-off, regardless of how many millions have gone into advertising. Regulatory affairs has moved from a support function to a business-critical one.
This article covers the components of an RA career: education, roles, global salaries, and specific entry steps for 2026.
Choosing the Right Education in 2026
Russian law does not require a specific diploma for RA work, but the labor market operates by its own rules. Employers line up for candidates with relevant backgrounds and pass over those pivoting from marketing or sales.
The Regulation on Licensing of Pharmaceutical Activities (Government Decree No. 547 of March 31, 2022) sets formal requirements for certain positions. A QP — Qualified Person (уполномоченное лицо) on the manufacturing side must hold a higher degree in pharmacy, chemistry, or biology and have at least five years of experience in production and quality control. Most registration department roles carry no statutory requirement, but without a relevant degree, the career ceiling tends to be lower in practice.
Pharmaceutical Education
A pharmacist with regulatory knowledge remains the most sought-after profile. A pharmacy background gives working understanding of chemical processes, manufacturing technology, molecular stability, and quality requirements. A pharmacy graduate speaks the same language as production teams, expert reviewers, and regulators.
In Russia, 77 universities offer a «Pharmacy» programme. The leading ones include Sechenov University (First Moscow State Medical University), St. Petersburg Chemical-Pharmaceutical University (SPCPU), Kazan State Medical University, and Siberian State Medical University.
The spetsialitet takes five years. After graduating, students pass primary accreditation and can work as pharmacists. Transition into RA typically happens after one to two years of practice in a pharmacy, on a manufacturing site, or with a distribution company.
In 2026, pharmacy graduates typically move into medicinal product registration departments, post-registration variations (dossier changes) teams, QA — Quality Assurance functions in manufacturing, and QP positions under GMP — Good Manufacturing Practice.
The technical stack expected in 2026 covers working with eCTD 4.0 (electronic Common Technical Document) in specialist software such as LORENZ docuBridge, Ennov, or local equivalents; knowledge of EEC Council Decision No. 78; preparation of CTD (Common Technical Document) modules; and interaction with EAEU expert bodies.
Biotechnology Education
Biologics now exceed 30% of the EAEU market and that share continues to grow. Gene therapy, monoclonal antibodies, next-generation vaccines, and cell products all require specialists who understand living systems. Biotechnology graduates are indispensable in R&D and when registering innovative products.
Biotechnology graduates find the strongest demand in biologics and biosimilar registration, R&D centres and innovative start-ups, clinical trials of biological medicines, and multinational companies with a biotech focus.
The 2026 technical stack for this profile includes understanding of biological medicine specifications, working with biosimilar guidelines, knowledge of biological molecule characterisation requirements, and immunogenicity assessment.
Medical Education
Physicians are valued in PV — Pharmacovigilance and Medical Information departments. They can analyse clinical data, understand disease mechanisms, and explain how medicines work. For safety assessments and PSUR — Periodic Safety Update Report preparation, a medical degree provides a clear advantage.
In 2026, demand for PV specialists is rising as regulators tighten safety monitoring requirements. Companies are separating PV functions into two streams: medicinal product safety monitoring and medical device safety monitoring.
Physicians find the strongest fit in PV departments, medical affairs functions at pharmaceutical companies, clinical trials, and Medical Advisor or Medical Director roles.
The 2026 competency stack for this profile covers safety signal detection using AI tools, working with adverse reaction (AR) databases in E2B (R3) format, PSUR and PBRER preparation, and regulatory interaction on safety questions.
Legal Education
Law as a primary degree for RA works poorly — without understanding chemistry, biology, or manufacturing processes, a lawyer cannot evaluate dossier quality or navigate validation requirements. As a second or additional degree, however, legal training offers a real competitive edge.
A specialist combining pharmacy and law can prepare registration dossiers, defend company interests in disputes with regulators, work with patents and intellectual property, and review contracts with CROs — Contract Research Organizations — and manufacturers.
A «pharmacy + law» combination opens paths into regulatory consulting, legal departments at pharmaceutical companies, RA Director positions, and patent protection and intellectual property work.
The relevant competency stack includes administrative law knowledge, experience interacting with regulators, understanding of decision appeal procedures, and patent legislation.
Roles in Regulatory Affairs
By 2026, the boundaries between specialisations have hardened. «All-rounders» exist only in smaller businesses; in major companies and serious consulting firms, roles are clearly divided.
RA Specialist / Manager develops registration strategy (identifying the fastest and least expensive route), prepares the registration dossier in eCTD format, and handles correspondence with Ministry of Health and EEC expert reviewers. The main challenge in 2026 is navigating the post-transition EAEU period — juggling dossier alignment procedures for existing products alongside new registrations.
QA Manager / Qualified Person ensures each tablet in a pack matches what the dossier says. Manages the QMS — Quality Management System and prepares manufacturing sites for GMP inspections. The main challenge in 2026 is implementing remote inspections and working with electronic quality systems. EAEU GMP rules (EEC Council Decision No. 77) are now mandatory for all manufacturers.
PV Manager monitors adverse reactions after a product launches and uses automated databases to file reports with regulatory authorities. The main challenge in 2026 is Big Data analysis and safety signal detection using AI tools. EAEU PV requirements (EEC Council Decision No. 79) have tightened.
Medical / Regulatory Writer authors clinical overviews and summaries on efficacy and safety (eCTD Modules 2.4, 2.5, 2.6, 2.7). Translates study data into structured documents for regulators. The main challenge in 2026 is the high evidentiary standard — text without solid data does not pass expert review.
Table 1: Roles and Key Competencies in 2026
| Role | Main Tasks | Base Education | 2026 Competencies |
|---|---|---|---|
| RA Specialist | Dossier preparation, submission, responding to expert queries | Pharmacy, chemistry, biotech | eCTD 4.0 (LORENZ, Ennov), EAEU/EMA portals, EEC Decision No. 78 |
| QA Manager | Site audits, QMS, inspection readiness | Pharmacy, chemistry | ISO 13485, EAEU GMP (EEC Decision No. 77), validation, Data Integrity |
| PV Specialist | Safety monitoring, AR collection, report preparation | Medicine, pharmacy | Signal detection, E2B (R3), AI analytics, EEC Decision No. 79 |
| Medical Writer | Writing dossier sections, clinical trial protocols | Medicine, biology | ICH Guidelines, scientific writing, AI assistant tools |
| Regulatory Operations | Project management, coordination, timelines | Any relevant | Veeva Vault, MasterControl, project management |
The 2026 Competency Map
Knowing how to assemble document folders is no longer enough. A modern RA specialist needs the following stack:
| Skill | Why it matters in 2026 |
|---|---|
| EAEU law | EEC Council Decisions No. 78 (registration), No. 77 (GMP), No. 79 (PV) form the foundation. Without understanding mutual recognition, scaling sales across five Union countries is impossible |
| Digital literacy (eCTD 4.0) | XML dossier validation is now standard. Proficiency in specialist software (LORENZ docuBridge, Ennov, or local equivalents) is required — Word and PDF skills alone are insufficient |
| Legal English | ICH, FDA, and EMA guidelines are the reference point for complex cases. Local regulations frequently follow their logic |
| Data Integrity | Data cannot be «adjusted.» In 2026, the digital audit trail is transparent, and AI-driven regulatory algorithms detect inconsistencies |
| Negotiation skills | Responding to expert queries (Deficiency Letters) persuasively without damaging relationships — or conceding the company’s position |
2026 Salary Benchmarks
The shortage of specialists who can work under new EAEU rules has overheated the market. RA salaries run consistently 20–30% above comparable roles in R&D or manufacturing.
Table 2: Russia — Monthly Gross
Exchange rate: 1 USD ≈ 100 RUB
| Level | Russian Companies | Multinational Corporations |
|---|---|---|
| Junior (0–2 yrs) | ₽80,000 – 140,000 | ₽110,000 – 160,000 |
| Middle (3–5 yrs) | ₽180,000 – 300,000 | ₽280,000 – 400,000 |
| Senior (5–8 yrs) | ₽300,000 – 450,000 | ₽400,000 – 600,000 |
| Head of Department | ₽400,000 – 600,000 | ₽600,000 – 900,000 |
| Director | ₽600,000 – 900,000 | ₽1,000,000 – 1,500,000 + bonuses |
Moscow and St. Petersburg account for roughly 80% of vacancies, but remote work has become standard for middle and senior positions. Candidates from other regions can earn Moscow-level salaries without relocating.
Table 3: Kazakhstan and Other EAEU Countries — Monthly Gross
| Level | Kazakhstan (Almaty) | Belarus (Minsk) |
|---|---|---|
| Junior | $1,000 – 1,500 | $700 – 1,200 |
| Middle | $2,500 – 4,000 | $1,500 – 2,500 |
| Senior | $5,000 – 7,500 | $2,500 – 4,000 |
| Head / Director | $8,000 – 12,000+ | $4,000 – 6,000 |
In EAEU countries, the RA market is smaller but competition for talent is high. Kazakhstan is actively developing local manufacturing, which drives demand for GMP and registration specialists.
Table 4: Europe — Annual Gross
| Level | Germany | Switzerland | United Kingdom |
|---|---|---|---|
| Junior | €45,000 – 55,000 | CHF 80,000 – 95,000 | £30,000 – 40,000 |
| Middle | €55,000 – 75,000 | CHF 100,000 – 135,000 | £40,000 – 60,000 |
| Senior | €70,000 – 100,000 | CHF 130,000 – 160,000 | £60,000 – 85,000 |
| Director | €100,000 – 140,000 | CHF 170,000 – 200,000+ | £100,000 – 130,000 |
Switzerland leads in absolute figures, but the cost of living matches. Germany offers a strong salary-to-expenses ratio. Ireland has become a European hub for multinational pharmaceutical companies and actively hires for global RA projects.
Table 5: United States — Annual Gross
| Level | Range |
|---|---|
| Junior | $65,000 – 90,000 |
| Middle | $100,000 – 140,000 |
| Senior | $140,000 – 180,000 |
| Director | $180,000 – 250,000+ |
The US market offers the highest earning potential, particularly for specialists working on oncology products, biologics, and medical devices. Visa requirements and strong competition make relocation difficult.
CRO — Contract Research Organization note: base salaries at CROs may run lower, but project completion bonuses often close the gap.
Where to Work
Big Pharma. International corporations such as Pfizer, Novartis, Roche, Sanofi, AstraZeneca, Johnson & Johnson. High salaries, strong benefits packages, employer-funded training, and access to innovative products. Downsides: bureaucracy, narrow specialisation (you may spend a year solely on label updates), slow decision-making, and exposure to global corporate politics.
Local manufacturers. Companies such as R-Pharm, Biocad, Pharmstandard, Generium, Petrovax. Fast-moving environment, rapid advancement to department head level, real influence on business decisions, and a broad range of tasks. Downsides: heavy workload («needed yesterday»), frequent need to build processes from scratch, fewer resources for professional development.
Regulatory consulting. Firms such as OCT, Synergy Research, PharmaLex (global), Novamedica Consulting. Variety — one week you register a vaccine, the next you work on SaMD (Software as a Medical Device). An excellent school for early-career specialists. Downsides: tight deadlines, simultaneous management of multiple clients, high pace throughout.
CROs. IQVIA, Parexel, PPD, Syneos Health, OCT, Cromos Pharma. Consistent hiring, willingness to train juniors, and intensive experience in a short time. Downsides: project-based work, uneven workload, overruns during deadline periods.
Public sector. Expert centres and regulators: NCESMP — National Centre for Expertise of Medicines and Medical Devices (НЦЭСМП) for medicinal products, VNIIMT — All-Russian Research Institute of Medical Technology (ВНИИМТ) for medical devices, Roszdravnadzor. Unique «other side of the table» experience, deep insight into internal processes, and networking with regulators. Downsides: below-market salaries, especially at junior levels, strict hierarchy, bureaucracy.
Geography of the Labour Market
Russia
Since January 2026, the Russian market has been operating under a new set of rules. The transition period for national Marketing Authorizations (MAs) has been extended to December 31, 2027. Companies are simultaneously managing products under old and new procedures, and specialists who command both systems are in high demand.
By March 2026, the move to EAEU GMP rules is complete, with manufacturers undergoing inspections under the updated requirements. Demand for quality specialists with EAEU inspection experience is rising.
Russian labour market trends: mass hiring of eCTD 4.0 specialists; rising demand for EEC Decision No. 78 experience; remote work as the standard for middle and senior roles; competition for biologics and orphan medicine experts.
Europe
The European market is absorbing the consequences of the May 2021 Medical Devices Regulation (MDR), which raised the bar for certification. Many manufacturers have not yet adapted, and demand for RA specialists in medical devices remains high. Alongside this, regulation of digital therapeutics and SaMD is developing — a niche with strong pay and limited competition.
Key talent hubs: Basel (Switzerland, global headquarters of Novartis and Roche), Dublin (Ireland, European offices of US pharmaceutical majors), Frankfurt and Munich (Germany, manufacturing sites and regional offices).
USA and Remote Work
American salaries are the highest globally, but FDA-centric regulation differs substantially from European and Eurasian systems and demands specific knowledge. Boston, New Jersey, San Francisco, and San Diego concentrate the main biotech and pharmaceutical clusters. Visa constraints make relocation difficult for Russian candidates, but remote work for US companies is increasingly viable.
Around 60% of RA vacancies now offer hybrid or fully remote formats. A specialist in Kazan can work for a Moscow-based company; someone with strong English can work for an Irish office of a global corporation.
How to Enter the Field
The standard obstacle for newcomers: companies want candidates with experience, but experience requires a job. Several proven routes exist.
Route one — through adjacent roles. Many successful RA professionals arrived from pharmacies, manufacturing, or clinical trials. A pharmacist with retail experience understands assortment and trade requirements. A manufacturing employee who worked on a GMP site knows processes from the inside. A CRA — Clinical Research Associate understands clinical trials, which form a substantial part of any registration dossier. This path takes one to three years but provides a solid foundation.
Route two — through internships and junior positions. Large pharmaceutical companies offer internship programmes for final-year students and recent graduates. Internships run three to six months; the best participants are offered staff positions. Some companies open registration department assistant roles with no experience requirement. Starting salaries are modest (₽50,000–80,000, ~$500–800), but the role provides structured learning from practitioners. Search for vacancies titled Junior Regulatory Associate, Assistant to RA Manager, or Technical Assistant. Starting with archive work or packaging artwork checks is one of the most effective ways to learn requirements through practice.
Route three — through CROs. CROs handle regulatory and clinical outsourcing and hire continuously. Two to three years at a CRO can generate experience that would take five to seven years to accumulate inside a pharmaceutical company.
International Certifications
For work at international level, the RAC — Regulatory Affairs Certification from RAPS (Regulatory Affairs Professionals Society) is the most widely recognised credential, with over 15,000 certified professionals globally. RAPS offers two tracks: RAC Devices for medical device specialists and RAC Drugs for medicinal product specialists.
Eligibility requires at least three years of RA experience. The exam tests knowledge of FDA requirements, European regulations, ISO standards, and WHO guidelines. Exam fees are $590 for RAPS members and $740 for non-members.
According to RAPS data, RAC holders in North America earn on average 12% more than non-certified colleagues. In Russia and the CIS, the certification is valued most at multinational companies and in export-oriented work.
The European alternative is TOPRA (The Organisation for Professionals in Regulatory Affairs), which focuses on EU regulation and is recognised across EU member states.
English
Without B2 English or above, an RA career is capped at the local market. Multinationals conduct internal correspondence in English. Dossiers for the FDA and EMA are prepared in English. ICH conference proceedings, publications, and guidelines are English-only. The salary gap between specialists with fluent English and those without can reach a factor of two.
What to Do Now
Define your target specialisation. Medicinal products or medical devices? Biologics or small molecules? Registration, pharmacovigilance, or quality? The choice shapes your entire trajectory.
Study the foundational documents. Start with Federal Law No. 61-FZ «On the Circulation of Medicinal Products» (April 12, 2010), EEC Council Decision No. 78 on registration rules, and the GMP — Good Manufacturing Practice rules (Minpromtorg Order No. 916). These define the regulatory requirements base.
Bring English to B2. If your level is lower, this is the first investment to make — in time and money. Without it, international doors stay closed.
Find your entry point. Students: internships and junior positions. Professionals from adjacent fields: transition via quality, manufacturing, or clinical trials roles. Experienced practitioners: CROs or consulting.
Build a professional network. Follow sector-specific channels, join LinkedIn and Telegram communities, attend conferences (RegLek, Pharmaprom, ISPE). Many RA vacancies are filled through referrals.
Master digital tools. Learn to work with regulatory authority portals (the State Register of Medicinal Products — GRLS, the EAEU portal), document management systems (Veeva Vault, MasterControl), and basic AI tools for routine task automation.
Plan your certification. After three years of experience, consider RAC or other international credentials. It is a long-term career investment.
Pros and Cons
Regulatory affairs in 2026 is a field where structural talent shortages, rising salaries, and expanding remote work opportunities converge — with entry still requiring a relevant degree and genuine technical knowledge.
The case for entering RA is concrete: salaries at the middle and senior levels run 20–30% above comparable R&D and manufacturing roles; remote work is now standard for experienced specialists, which removes the need to relocate to Moscow or St. Petersburg; the EAEU transition has created sustained demand for dual-competency specialists over several years ahead, not just a short-term spike. For physicians and pharmacists in particular, PV and registration roles represent one of the highest-earning pivot paths available without surgical or narrow clinical specialisation.
The barriers are equally concrete. Entry-level salaries (₽50,000–80,000) are modest and require patience. The EAEU regulatory framework is technically demanding and still evolving — what a specialist knows today may need updating by 2027. Without English at B2 or above, access to multinational salaries and international work is effectively closed. And building from junior to senior takes five to eight years of consistent effort.
The field rewards specialists who treat regulatory knowledge as a technical discipline, not a document management function. Those who invest in eCTD skills, EAEU law, and English now are positioned for roles that were senior-level five years ago.
Regulatory Basis
- Federal Law No. 61-FZ of April 12, 2010 «On the Circulation of Medicinal Products»
- Government Decree No. 547 of March 31, 2022 «On Approval of the Regulation on Licensing of Pharmaceutical Activities»
- EEC Council Decision No. 78 of November 3, 2016 «On the Rules for Registration and Expert Evaluation of Medicinal Products for Medical Use»
- EEC Council Decision No. 79 of November 3, 2016 «On the Rules for Conducting Pharmaceutical Inspections»
- EEC Council Decision No. 77 of November 3, 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union»
- Minpromtorg Order No. 916 of June 14, 2013 «On Approval of the Good Manufacturing Practice Rules»
Sources: Federal Law No. 61-FZ of April 12, 2010; Government Decree No. 547 of March 31, 2022; EEC Council Decisions No. 77, 78, 79 of November 3, 2016; Minpromtorg Order No. 916 of June 14, 2013; RAPS salary survey data (raps.org); vacancy data from hh.ru; kugno.ru, 2026.
Other articles on Regulatory Affairs →